ES2123177T3 - Preparacion de absorcion percutanea que contiene buprenorfina. - Google Patents
Preparacion de absorcion percutanea que contiene buprenorfina.Info
- Publication number
- ES2123177T3 ES2123177T3 ES95106861T ES95106861T ES2123177T3 ES 2123177 T3 ES2123177 T3 ES 2123177T3 ES 95106861 T ES95106861 T ES 95106861T ES 95106861 T ES95106861 T ES 95106861T ES 2123177 T3 ES2123177 T3 ES 2123177T3
- Authority
- ES
- Spain
- Prior art keywords
- buprenorphine
- percutaneous absorption
- penetration enhancer
- absorption preparation
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE HA OBTENIDO UNA PREPARACION DE ABSORCION PERCUTANEA QUE ES EXCELENTE PARA LA PENETRACION EN LA PIEL DE UNA BUPRENORFINA ANALGESICA NO-NARCOTICA Y PUEDE MANTENER UN NIVEL DE SANGRE ALTO EN UN ESTADO ESTABLE POR ENCIMA DE UN LARGO PERIODO DE TIEMPO. LA PREPARACION DE ABSORCION PERCUTANEA PARA ADMINISTRAR HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, CONTIENE UN SOPORTE QUE TIENE EN UNA SUPERFICIE DEL MISMO UNA CAPA DE ESCAYOLA QUE CONTIENE UN ADHESIVO SENSIBLE A LA PRESION, HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA, UN INTENSIFICADOR DE LA PENETRACION, EN DICHO INTENSIFICADOR DE LA PENETRACION SE CONTIENE UNA COMBINACION DE DE UN MONOGLICERIDO DE UN ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y MIRISTATO DE ISOPROPILO, Y LA CAPA DE ESCAYOLA CONTIENE AL MENOS EL 10 DE SU PESO DE UN MONOGLICERIDO O ACIDO GRASO QUE TIENE DE 6 A 8 ATOMOS DE CARBONO Y AL MENOS 5 DEL PESO DE MIRISTATO DE ISOPROPILO, CON LA CONDICION DE QUE EL CONTENIDO DE TODO EL INTENSIFICADOR DE PENETRACION OSCILE ENTRE EL 25 Y EL 50 DEL PESO. EL USO COMBINADO DEL MONOGLICERIDO DE ACIDO GRASO Y EL MIRISTATO DE ISOPROPILO COMO INTENSIFICADOR DE LA PENETRACION SINERGETICAMENTE ELEVAN LA PENETRACION EN LA PIEL DEL HIDROCLORURO DE BUPRENORFINA Y/O BUPRENORFINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6094241A JP2819236B2 (ja) | 1994-05-06 | 1994-05-06 | 経皮吸収製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2123177T3 true ES2123177T3 (es) | 1999-01-01 |
Family
ID=14104817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95106861T Expired - Lifetime ES2123177T3 (es) | 1994-05-06 | 1995-05-05 | Preparacion de absorcion percutanea que contiene buprenorfina. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5618555A (es) |
EP (1) | EP0680754B1 (es) |
JP (1) | JP2819236B2 (es) |
KR (1) | KR950031058A (es) |
CN (1) | CN1116525A (es) |
AT (1) | ATE171619T1 (es) |
CA (1) | CA2147918A1 (es) |
DE (1) | DE69505041T2 (es) |
ES (1) | ES2123177T3 (es) |
TW (1) | TW325406B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3576608B2 (ja) | 1994-11-15 | 2004-10-13 | 日東電工株式会社 | 貼付剤および貼付製剤 |
JPH1036265A (ja) * | 1996-07-19 | 1998-02-10 | Nitto Denko Corp | ブプレノルフィン経皮吸収製剤 |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
ATE510542T1 (de) * | 1997-09-04 | 2011-06-15 | Novoneuron Inc | Noribogain zur behandlung von schmerzen und drogenabhängigkeit |
US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
JP4659943B2 (ja) | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
WO2001093868A1 (fr) * | 2000-06-02 | 2001-12-13 | Teijin Limited | Bande adhesive contenant de la buprenorphine |
KR100448469B1 (ko) * | 2001-10-26 | 2004-09-13 | 신풍제약주식회사 | 항염증제의 경피 조성물 및 장치 |
PT2561860T (pt) * | 2002-05-31 | 2018-05-08 | Titan Pharmaceuticals Inc | Dispositivo polimérico implantável para a libertação prolongada de buprenorfina |
KR20110120358A (ko) * | 2002-06-10 | 2011-11-03 | 유로-셀티크 소시에떼 아노뉨 | 경피 전달 장치에 포함된 활성 성분의 오용을 방지하는 경피 전달 장치의 처리 시스템 |
ES2359977T3 (es) | 2003-03-31 | 2011-05-30 | Titan Pharmaceuticals, Inc. | Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina. |
PT1646328E (pt) | 2003-07-25 | 2007-10-24 | Euro Celtique Sa | Tratamento da abstinência de dependência. |
WO2006085521A1 (ja) * | 2005-02-10 | 2006-08-17 | Nihon University | オピオイドレセプター拮抗剤を含有する経皮吸収用医薬組成物およびその製造方法、並びに前記拮抗剤の経皮吸収促進方法 |
EP1854456B1 (en) * | 2005-02-28 | 2017-08-23 | Hisamitsu Pharmaceutical Co., Inc. | Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base |
NZ590950A (en) * | 2008-07-18 | 2012-12-21 | Biomod Concepts Inc | Articles of manufacture releasing an active ingredient |
TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
RU2586296C2 (ru) | 2010-07-23 | 2016-06-10 | Демеркс, Инк. | Композиции норибогаина |
EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
EP2788003A4 (en) | 2011-12-09 | 2015-05-27 | Demerx Inc | PHOSPHATESTER OF NORIBOGAIN |
EP2807168A4 (en) | 2012-01-25 | 2015-10-14 | Demerx Inc | SYNTHETIC VOACANGINE |
US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
CA2896133A1 (en) | 2012-12-20 | 2014-06-26 | Demerx, Inc. | Substituted noribogaine |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
JP6695571B2 (ja) * | 2016-12-05 | 2020-05-20 | 王子ホールディングス株式会社 | 経皮吸収型製剤 |
CN109487582A (zh) * | 2018-11-19 | 2019-03-19 | 长沙浩然医疗科技有限公司 | 一种纯棉织物面料印染工艺 |
CN110013602B (zh) * | 2019-04-17 | 2021-10-26 | 杨高云 | 用于治疗肢端型白癜风的手套及其制备方法 |
US11584110B2 (en) | 2020-07-30 | 2023-02-21 | Pepsico, Inc. | Multi-layered packaging films |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CH672888A5 (es) * | 1986-11-07 | 1990-01-15 | Mepha Ag | |
AU630347B2 (en) * | 1988-02-26 | 1992-10-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5026556A (en) * | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
EP0413034B1 (en) * | 1989-02-28 | 1993-09-29 | Teijin Limited | Poultice and preparation thereof |
US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
EP0474647B1 (en) * | 1990-03-28 | 1997-02-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5238933A (en) * | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
-
1994
- 1994-05-06 JP JP6094241A patent/JP2819236B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-26 CA CA002147918A patent/CA2147918A1/en not_active Abandoned
- 1995-04-28 US US08/430,384 patent/US5618555A/en not_active Expired - Fee Related
- 1995-05-03 TW TW084104420A patent/TW325406B/zh active
- 1995-05-05 AT AT95106861T patent/ATE171619T1/de not_active IP Right Cessation
- 1995-05-05 ES ES95106861T patent/ES2123177T3/es not_active Expired - Lifetime
- 1995-05-05 DE DE69505041T patent/DE69505041T2/de not_active Expired - Fee Related
- 1995-05-05 EP EP95106861A patent/EP0680754B1/en not_active Expired - Lifetime
- 1995-05-06 CN CN95107104A patent/CN1116525A/zh active Pending
- 1995-05-06 KR KR1019950011072A patent/KR950031058A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW325406B (en) | 1998-01-21 |
DE69505041T2 (de) | 1999-02-18 |
CN1116525A (zh) | 1996-02-14 |
EP0680754A2 (en) | 1995-11-08 |
US5618555A (en) | 1997-04-08 |
CA2147918A1 (en) | 1995-11-07 |
JPH07304672A (ja) | 1995-11-21 |
KR950031058A (ko) | 1995-12-18 |
ATE171619T1 (de) | 1998-10-15 |
EP0680754B1 (en) | 1998-09-30 |
EP0680754A3 (en) | 1996-03-06 |
JP2819236B2 (ja) | 1998-10-30 |
DE69505041D1 (de) | 1998-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2123177T3 (es) | Preparacion de absorcion percutanea que contiene buprenorfina. | |
AU7396294A (en) | Incorporating poly-n-vinyl amide in a transdermal system | |
HU9802889D0 (en) | Percutaneous absorption type preparation | |
MX9206577A (es) | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES | |
PT738512E (pt) | Utilizacao de um inibidor da hmg-coa-reductase para evitar um segundo ataque cardiaco | |
ES2093747T3 (es) | Composicion farmaceutica que contiene felbinac. | |
DE69420419T2 (de) | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern | |
EP0211354A3 (en) | Nucleosides and their use as antineoplastic agents | |
NO894465L (no) | Preparat med oekt penetrasjon gjennom huden. | |
ES2040633A1 (es) | Un procedimiento para la preparacion de una composicion oral antihalitosica. | |
MY118301A (en) | Local anesthetic for external use | |
CA2146723A1 (en) | Percutaneous absorption preparation | |
DE59410151D1 (de) | Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe | |
KR900007424A (ko) | 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물 | |
KR910018020A (ko) | 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법 | |
PE20001325A1 (es) | Combinacion de cerivastatina y fibratos | |
DK0565519T3 (da) | Illudinanaloge som antitumormidler | |
JPS6468316A (en) | External plaster containing salbutamol | |
KR970014571A (ko) | 1,2-디브로모-2,4-디시아노부탄과 파라하이드록시벤조산 에스테르와의 상승작용성 항미생물성 조성물 | |
CA2170485A1 (en) | Compositions Containing an Amino Acid Salt of Propionic Acid Non-Steroidal Anti-Inflammatory Agents and Caffeine | |
JPS5791913A (en) | Pharmaceutical preparation of drug | |
DK1062954T3 (da) | Anvendelse af itakonsyre til regulering af det glykotiske stofskifte | |
KR100387397B1 (es) | ||
ES2158937T3 (es) | Parche que contiene dinitrato de isosorbida y que se prepara utilizando una mezcla de adhesivos. | |
AU1783699A (en) | Compositions for the transdermal and dermal administration of biologically active agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 680754 Country of ref document: ES |